YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
105 hedge funds and large institutions have $339M invested in Y-mAbs Therapeutics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
9% more funds holding
Funds holding: 96 → 105 (+9)
2.25% more ownership
Funds ownership: 55.49% → 57.75% (+2.3%)
Holders
105
Holding in Top 10
1
Calls
$563K
Puts
$5K
Top Buyers
| 1 | +$10.1M | |
| 2 | +$7.77M | |
| 3 | +$5.14M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.73M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$2.38M |
Top Sellers
| 1 | -$3.53M | |
| 2 | -$3.34M | |
| 3 | -$3.14M | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.76M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.76M |